Kiniksa (KNSA) PT Raised to $37 at BofA Securities After the FDA Approved Rilonacept
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham raised the price target on Kiniksa (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE